A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir
| Autor: | Xie Xiaolin, Li Han, Lei Tian, Tang Yonghong, Zhang Dezhu, Zhenfeng Shi, Qiao Guaiping, Xu Zhao, Hui Nan, Liu Yuzhi, Liang Chengyuan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Drug
Emergency Use Authorization Coronavirus disease 2019 (COVID-19) viruses media_common.quotation_subject Pneumonia Viral Review Article Bioinformatics medicine.disease_cause Antiviral Agents 01 natural sciences Betacoronavirus 03 medical and health sciences Pharmacokinetics Drug Discovery Pandemic medicine Humans Antiviral Pandemics 030304 developmental biology media_common Coronavirus Pharmacology Clinical Trials as Topic 0303 health sciences Alanine SARS-CoV-2 010405 organic chemistry Chemistry Organic Chemistry COVID-19 General Medicine Adenosine Monophosphate COVID-19 Drug Treatment 0104 chemical sciences Clinical trial RdRP inhibitor Pharmacodynamics Coronavirus Infections Remdesivir (GS-5734) |
| Zdroj: | European Journal of Medicinal Chemistry |
| ISSN: | 0223-5234 |
| DOI: | 10.1016/j.ejmech.2020.112527 |
| Popis: | Remdesivir (GS-5734), a viral RNA-dependent RNA polymerase (RdRP) inhibitor that can be used to treat a variety of RNA virus infections, is expected to be an effective treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. On May 1, 2020, The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for remdesivir to treat COVID-19 patients. In light of the COVID-19 pandemic, this review presents comprehensive information on remdesivir, including information regarding the milestones, intellectual properties, anti-coronavirus mechanisms, preclinical research and clinical trials, and in particular, the chemical synthesis, pharmacology, toxicology, pharmacodynamics and pharmacokinetics of remdesivir. Furthermore, perspectives regarding the use of remdesivir for the treatment of COVID-19 are also discussed. Graphical abstract Image 1 Highlights • This article provides a comprehensive overview of remdesivir (GS-5734). • Remdesivir inhibits a variety of RNA viruses, including Coronaviridae, Filoviridae, Paramyxoviridae and Arenaviridae . • The remdesivir synthetic routes were comprehensively collected and are presented as a compilation of roadmaps. • The mechanism and clinical trial information of remdesivir for the treatment of COVID-19 are summarized. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect